Drug Combination Details
| General Information of the Combination (ID: C54915) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [2] | |||
|
Renal cell carcinoma
[ICD-11: 2C90]
|
Investigative | [3] | |||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [4] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cathepsin B release | ||||
| In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| S2-VP10 | CVCL_F972 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. | |||||
| Experiment 2 Reporting the Effect of This Combination | [6] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | HuCC-A1 | CVCL_M255 | Intrahepatic cholangiocarcinoma | Homo sapiens | ||
| KKU-100 | CVCL_3996 | Hilar cholangiocarcinoma | Homo sapiens | |||
| KKU-M139 | CVCL_M259 | Intrahepatic cholangiocarcinoma | Homo sapiens | |||
| KKU-213C | CVCL_M260 | Cholangiocarcinoma | Homo sapiens | |||
| KKU-213B | CVCL_M264 | Cholangiocarcinoma | Homo sapiens | |||
| HubCCA-1 | Cholangiocarcinoma | Homo sapiens | ||||
| Experimental
Result(s) |
The combination of TRAIL and triptolide could enhance susceptibility to TRAIL-induced apoptotic killing in these TRAIL-resistant CCA cells. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | COL11A2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-ChA-1 | CVCL_6952 | Cholangiocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
TRAIL and triptolide in combination decreased cell viability and enhanced apoptosis. | |||||
| Experiment 4 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDK2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | IFI27 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PUM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
TPL enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1. | |||||
| Experiment 5 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | HSPA4 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | ACHN | CVCL_1067 | Papillary renal cell carcinoma | Homo sapiens | ||
| A-498 | CVCL_1056 | Renal cell carcinoma | Homo sapiens | |||
| Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | |||
| 769-P | CVCL_1050 | Renal cell carcinoma | Homo sapiens | |||
| 786-O | CVCL_1051 | Renal cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Triptolide sensitizes RCC cells to TRAIL-induced apoptosis through altered TRAIL death receptor and heat shock protein expression. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [7] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MIA-PaCa | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combined therapy with triptolide and TRAIL significantly decreased the cell viability in all the cell lines and increased apoptotic cell death as a result of caspase-3 and caspase-9 activation. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | OCI-AML-3 | CVCL_1844 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. | |||||
